University of North Carolina
Chapel Hill, North Carolina, 27599, United States
NCT Number: NCT01217359
Purpose:
The purpose of this exploratory study is to evaluate phosphoprotein profiling to determine differences in the intracellular actions of interferon or interferon stimulated genes among people with different treatment outcomes to interferon based therapy for hepatitis C (HCV). Participants: Patients with genotype 1 HCV who have had interferon based therapy at the University of North Carolina (UNC). Procedures: Thirty patients with varied responses to treatment will be given a single subcutaneous injection of interferon alpha 2b. Prior to the injection and at 30 minutes, 1,2,4,6,12 and 20 hours after injection, blood will be drawn for analysis of phosphoprotein profiling and changes in serum cytokines.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Chapel Hill, North Carolina, 27599, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
To be eligible for this study, subjects must meet the following inclusion criteria:
Exclusion criteria
Subjects with any of the following will not be eligible for participation:
Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
Other names: Intron A
Time frame: 0-20 hours
This is an exploratory study observing downstream phosphorylation of interferon stimulated genes in the Janus Activated Kinase (JAK-STAT) pathway.
University of North Carolina, Chapel Hill
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03935906
Blood-Borne Infections, Communicable Diseases
Melbourne, Australia
View Trial DetailsNCT00004850
Blood-Borne Infections, Communicable Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05208697
Blood-Borne Infections, Communicable Diseases
Fort Lauderdale, Florida, United States
View Trial DetailsNCT03222531
Blood-Borne Infections, Cardiac Transplant
Pittsburgh, Pennsylvania, United States
View Trial Details